The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841
Open accessAbstract
Purpose: Symptoms and complications of metastatic colorectal cancer (mCRC) differ by metastatic sites. There is a paucity of prospective survival data for patients with peritoneal carcinomatosis colorectal cancer (pcCRC). We characterized outcomes of patients with pcCRC enrolled onto two prospective randomized trials of chemotherapy and contrasted that with other manifestations of mCRC (non-pcCRC). Methods: A total of 2,095 patients enrolled onto two prospective randomized trials were evaluated for overall survival (OS) and progression-free survival (PFS). A Cox proportional hazard model was used to assess the adjusted associations. Results: The characteristics of the pcCRC group (n = 364) were similar to those of the non-pcCRC patients in median age (63 v 61 years, P = .23), sex (57% males v 61%, P = .23), and performance status (Eastern Cooperative Oncology Group performance status 0 or 1 94% v 96%, P = .06), but differed in frequency of liver (63% v 82%, P < .001) and lung metastases (27% v 34%, P = .01). Median OS (12.7 v 17.6 months, hazard ratio [HR] = 1.3; 95% CI, 1.2 to 1.5; P < .001) and PFS (5.8 v 7.2 months, HR = 1.2; 95% CI, 1.1 to 1.3; P = .001) were shorter for pcCRC versus non-pcCRC. The unfavorable prognostic influence of pcCRC remained after adjusting for age, PS, liver metastases, and other factors (OS: HR = 1.3, P < .001; PFS: HR = 1.1, P = .02). Infusional fluorouracil, leucovorin, and oxaliplatin was superior to irinotecan, leucovorin, and fluorouracil as a first-line treatment among pcCRC (HR for OS = 0.62, P = .005) and non-pcCRC patients (HR = 0.66, P < .001). Conclusion: pcCRC is associated with a significantly shorter OS and PFS as compared with other manifestations of mCRC. Future trials for mCRC should consider stratifying on the basis of pcCRC status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Self-citationVerwaal, V. J., van Ruth, S., de Bree, E., van Slooten, G. W., van Tinteren, H., Boot, H., & Zoetmulder, F. A. N. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.187 · Cited by 2,049
Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., Walpole, E. T., Finch-Jones, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60455-9 · Cited by 1,937
Abdalla, E. K., Vauthey, J.-N., Ellis, L. M., Ellis, V., Pollock, R., Broglio, K. R., Hess, K., & Curley, S. A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000128305.90650.71 · Cited by 1,750
Sadeghi, B., Arvieux, C., Glehen, O., Beaujard, A. C., Rivoire, M., Baulieux, J., Fontaumard, E., Brachet, A., Caillot, J. L., Faure, J. L., et al. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o · Cited by 1,200
Glehen, O., Kwiatkowski, F., Sugarbaker, P. H., Elias, D., Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.012 · Cited by 1,184
Pawlik, T. M., Scoggins, C. R., Zorzi, D., Abdalla, E. K., Andres, A., Eng, C., Curley, S. A., Loyer, E. M., Muratore, A., Mentha, G., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000160703.75808.7d · Cited by 1,101
Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G., & van Tinteren, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9966-2 · Cited by 1,033
Elias, D., Lefevre, J. H., Chevalier, J., Brouquet, A., Marchal, F., Classe, J.-M., Ferron, G., Guilloit, J.-M., Meeus, P., Goéré, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7160 · Cited by 876
Cited by
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.004 · Cited by 858
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772
Klaver, C. E. L., Wisselink, D. D., Punt, C. J. A., Snaebjornsson, P., Crezee, J., Aalbers, A. G. J., Brandt, A., Bremers, A. J. A., Burger, J. W. A., Fabry, H. F. J., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30239-0 · Cited by 322
Liu, T., Wang, X., Hu, W., Fang, Z., Jin, Y., Fang, X., & Miao, Q. R. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.011 · Cited by 41
Metadata
- Authors
- Franko, J., Shi, Q., Goldman, C. D., Pockaj, B. A., Nelson, G. D., Goldberg, R. M., Pitot, H. C., Grothey, A., Alberts, S. R., & Sargent, D. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-01-20
- Volume
- 30
- Issue
- 3
- Pages
- 263-267
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2109794223
- Cited by
- 587
- References
- 20
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. https://app.cochat.ai/papers/10.1200/jco.2011.37.1039
- The paper
- Franko, J., Shi, Q., Goldman, C. D., Pockaj, B. A., Nelson, G. D., Goldberg, R. M., Pitot, H. C., Grothey, A., Alberts, S. R., & Sargent, D. J. (2012). Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.37.1039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
